查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1726288

全球药物基因体学技术市场：市场规模、份额、趋势分析（按治疗领域、技术和地区）、细分市场预测（2025-2030 年）

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report By Therapeutic Area (Neurological Disorders, Cardiovascular Disease), By Technology (PCR, In-situ Hybridization), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

药物基因体学技术市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球药物基因体学技术市场预计到2030年将达到123.8亿美元，2025年至2030年期间的复合年增长率为8.1%。

诊断学正在适应药物基因体学检测的兴起，以及随之而来的新生物疗法。这些测试可以实现具有成本效益的治疗，同时也为药物开发过程增加了价值。与传统方法相比，这些测试具有许多优势，例如疾病风险预测、患者分层和治疗反应监测，并有望成为药物基因体学伴随诊断市场取得重大进步的来源。

此外，药物基因体学测试产品可帮助医生个人化和优化患者治疗方法。药物基因体学和治疗诊断学正在为整合医学铺平道路。这套专门的分子诊断测试的快速发展有助于改善疾病的即时治疗评估。

然而，将基于药物基因体学的测试早期整合到药物开发时间表中并同时获得核准所面临的挑战预计会阻碍成长。正确设计和执行临床试验以识别特定治疗导致的个体和群体差异已成为治疗诊断学成功的必要属性。

药物基因体学技术市场：概述

  • 到 2024 年，肿瘤学将占据治疗领域的主导地位，份额接近 40%。
  • 精准肿瘤学研究人员使用多种药物以不同的组合来消除肿瘤，而不是简单地减缓其生长。
  • 在治疗诊断学技术方面，聚合酵素链锁反应（PCR）占据市场主导地位。 PCR技术因其诸多优点，被广泛应用于临床诊断，并成为该领域的重要技术。
  • 由于药物开发商有将其产品与诊断技术结合的经济奖励，北美地区在药物基因体学技术市场占据主导地位。
  • 由于企业寻求利用尚未开发的商业机会，预计亚太地区将在预测期内见证最快的成长。
  • 药物基因组学技术市场的主要企业包括 QIAGEN、GE HealthCare、安捷伦科技公司、F. Hoffmann-La Roche Ltd.、FOUNDATION MEDICINE, INC.、Oxford 药物基因体学 Technologies plc.、Twist Bioscience、赛默飞世瑞尔科技公司、Leica Biosystems Nusslo Technologies plc.、Twist Bioscience、赛默飞世瑞尔科技公司、Leica Biosystems Nussloch GmB。
  • FOUNDATION MEDICINE, INC. 于 2024 年 11 月宣布，美国食品药物管理局(FDA) 已批准 FoundationOne Liquid CDx 作为合作伙伴诊断，用于识别患有 MET 外显子 14 跳跃改变的非小细胞肺癌 (NSCLC) 患者，这些患者有核准接受 TEPMETKO（Erlotinib）治疗。这种基于血液的测试将有助于有标靶治疗决策，并透过药物基因组学分析支持精准肿瘤学。

目录

第一章 分析方法与范围

第二章执行摘要

第三章药物基因体学技术市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 药物基因体学技术市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章药物基因体学技术市场：按治疗领域的估计和趋势分析

  • 治疗区域仪表板
  • 药物基因体学技术市场：按治疗领域进行的变异分析
  • 全球药物基因体学技术市场：按治疗领域分類的市场规模预测和趋势分析（2018-2030）
  • 瘤
    • 市场估计与预测（2018-2030）
    • 肺癌
    • 乳癌
    • 大肠直肠癌
    • 子宫颈癌
    • 其他的
  • 神经系统疾病
    • 市场估计与预测（2018-2030）
  • 心血管疾病
    • 市场估计与预测（2018-2030）
  • 免疫疾病
    • 市场估计与预测（2018-2030）
  • 感染疾病
    • 市场估计与预测（2018-2030）
  • 其他的
    • 市场估计与预测（2018-2030）

第五章药物基因体学技术市场：按技术进行的估计和趋势分析

  • 特定于技术的仪表板
  • 药物基因体学技术市场：依技术进行差异分析
  • 全球药物基因体学技术市场：市场规模预测与技术趋势分析（2018-2030）
  • PCR
  • 原位杂合反应
  • 免疫组织化学
  • 定序
  • 其他的

第六章药物基因体学技术市场：按地区估计和趋势分析

  • 市场仪表板：按地区
  • 各地区市场占有率分析（2024 年及 2030 年）
  • 药物基因体学技术市场：按地区分類的关键要点
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要企业热力图分析（2024年）
  • 公司简介
    • QIAGEN
    • GE HealthCare
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd
    • FOUNDATION MEDICINE, INC
    • Thermo Fisher Scientific Inc.
    • Oxford Nanopore Technologies plc.
    • Twist Bioscience
    • Leica Biosystems Nussloch GmBH
    • Pfizer Inc
    • Abbott
Product Code: GVR-1-68038-940-1

Pharmacogenomics Technology Market Growth & Trends:

The global pharmacogenomics technology market is anticipated to reach USD 12.38 billion by 2030 and is anticipated to expand at a CAGR of 8.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Diagnostics is adapting to the rise of pharmacogenomic tests, which are followed by the addition of new biological treatments. These tests enable cost-effective treatment and also add value to the process of drug development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to a significant source of progress in this pharmacogenomics companion diagnostics market.

In addition, pharmacogenomics testing products aid physicians in individualizing and optimization of the patient's therapeutic regimen. Pharmacogenomics and theranostics are paving the way for integrated medicine. Rapid evolution in this group of specialized molecular diagnostic tests is contributing to improvement for the assessment of real-time treatment of disease.

However, the presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development timelines for gaining approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy have become a necessary attribute for the success of theranostics.

Pharmacogenomics Technology Market Report Highlights:

  • Oncology dominated the therapeutic area segment with nearly 40% share in 2024, driven by the presence of a substantial number of products
  • Precision oncology researchers aim to use multiple medications in various combinations to eliminate tumors rather than merely slowing their growth
  • Polymerase Chain Reaction (PCR) dominated the market the with respect to technology for theranostics. The PCR technique is widely used in clinical diagnostics due to its numerous advantages, making it a key method in the field.
  • North American region dominates the pharmacogenomics technology market because of economic incentives for drug developers to pair their products with diagnostics
  • Asia Pacific market is projected to showcase the fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities
  • Key players operating in the pharmacogenomics technology market include QIAGEN; GE HealthCare.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd; FOUNDATION MEDICINE, INC.; Oxford Nanopore Technologies plc.; Twist Bioscience.; Thermo Fisher Scientific Inc.; Leica Biosystems Nussloch GmBH; Pfizer Inc.; Abbott
  • In November 2024, FOUNDATION MEDICINE, INC. announced that the U.S. Food and Drug Administration (FDA) had approved FoundationOne Liquid CDx as a partner diagnostic to identify patients with MET exon 14 skipping alterations in non-small cell lung cancer (NSCLC) eligible for treatment with TEPMETKO(erlotinib). This blood-based test helps guide targeted therapy decisions, supporting precision oncology through pharmacogenomic profiling.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapeutic area
    • 1.2.2. Technology
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapeutic area outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmacogenomics Technology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Pharmacogenomics Technology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis

  • 4.1. Therapeutic Area Dashboard
  • 4.2. Pharmacogenomics Technology Market: Therapeutic Area Movement Analysis
  • 4.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 4.4. Oncology
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Lung Cancer
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Breast Cancer
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Colorectal Cancer
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Cervical Cancer
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Neurological Disorders
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Cardiovascular Disorders
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Immunological Disorders
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Infectious Diseases
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmacogenomics Technology Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Segment Dashboard
  • 5.2. Pharmacogenomics Technology Market: Technology Movement Analysis
  • 5.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 5.4. PCR
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. In-situ Hybridization
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Immunohistochemistry
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Sequencing
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmacogenomics Technology Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Pharmacogenomics Technology Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Mexico
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Norway
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/ reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework/ reimbursement structure
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Australia
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Argentina
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework/ reimbursement structure
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. QIAGEN
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. GE HealthCare
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Agilent Technologies, Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. F. Hoffmann-La Roche Ltd
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. FOUNDATION MEDICINE, INC
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Thermo Fisher Scientific Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Oxford Nanopore Technologies plc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Twist Bioscience
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Leica Biosystems Nussloch GmBH
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Pfizer Inc
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Abbott
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives

List of Tables

  • Table 1. List of abbreviations
  • Table 2. Global pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 3. Global pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 4. Global pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 5. North America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 6. North America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 7. North America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 8. U.S. laboratory pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 9. U.S. pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 10. U.S. pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 11. Canada pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 12. Canada pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 13. Canada pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 14. Mexico pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 15. Mexico pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 16. Mexico pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 17. Europe pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 18. Europe pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 19. Europe pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 20. Germany pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 21. Germany pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 22. Germany pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 23. UK pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 24. UK pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 25. UK pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 26. France pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 27. France pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 28. France pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 29. Italy pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 30. Italy pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 31. Italy pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 32. Spain pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 33. Spain pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 34. Spain pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 35. Denmark pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 36. Denmark pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 37. Denmark pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 38. Sweden pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 39. Sweden pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 40. Sweden pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 41. Norway pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 42. Norway laboratory proficiency testing market, by technology, 2018 - 2030 (USD Million)
  • Table 43. Norway pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 44. Asia Pacific pharmacogenomics technology market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 47. China pharmacogenomics technology market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 48. China pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 49. China pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 50. Japan pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 51. Japan pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 52. Japan pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 53. India pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 54. India pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 55. India pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 56. South Korea pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 57. South Korea pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 58. South Korea pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 59. Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 60. Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 61. Australia pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 62. Thailand pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 63. Thailand pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 64. Thailand pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 65. Latin America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 66. Latin America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 67. Latin America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 68. Brazil pharmacogenomics technology, therapeutic area, 2018 - 2030 (USD Million)
  • Table 69. Brazil pharmacogenomics technology, by technology, 2018 - 2030 (USD Million)
  • Table 70. Brazil pharmacogenomics technology, by region, 2018 - 2030 (USD Million)
  • Table 71. Argentina pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 72. Argentina pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 73. Argentina pharmacogenomics technology market, by end region, 2018 - 2030 (USD Million)
  • Table 74. MEA pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 75. MEA pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 76. MEA pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 77. South Africa pharmacogenomics technology testing market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 78. South Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 79. South Africa pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 80. Saudi Arabia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 81. Saudi Arabia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 82. Saudi Arabia pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 83. UAE pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 84. UAE pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 85. UAE pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 86. Kuwait pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 87. Kuwait pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 88. Kuwait pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Pharmacogenomics technology: market outlook
  • Fig. 10 Pharmacogenomics technology: competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Pharmacogenomics technology market driver impact
  • Fig. 16 Pharmacogenomics technology market restraint impact
  • Fig. 17 Pharmacogenomics technology market strategic initiatives analysis
  • Fig. 18 Pharmacogenomics technology market: Therapeutic area analysis
  • Fig. 19 Pharmacogenomics technology market: Therapeutic area outlook and key takeaways
  • Fig. 20 Oncology market estimates and forecast, 2018 - 2030
  • Fig. 21 Neurological disorders market estimates and forecast, 2018 - 2030
  • Fig. 22 Cardiovascular diseases market estimates and forecast, 2018 - 2030
  • Fig. 23 Immunological disorders market estimates and forecast, 2018 - 2030
  • Fig. 24 Infectious diseases market estimates and forecast, 2018 - 2030
  • Fig. 25 Others market estimates and forecast, 2018 - 2030
  • Fig. 26 Pharmacogenomics technology market: Technology movement analysis
  • Fig. 27 Pharmacogenomics technology market: Technology outlook and key takeaways
  • Fig. 28 PCR market estimates and forecasts, 2018 - 2030
  • Fig. 29 In-situ hybridization market estimates and forecasts, 2018 - 2030
  • Fig. 30 Immunohistochemistry market estimates and forecasts, 2018 - 2030
  • Fig. 31 Sequencing market estimates and forecasts, 2018 - 2030
  • Fig. 32 Others market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global Pharmacogenomics technology market: Regional movement analysis
  • Fig. 34 Global Pharmacogenomics technology market: Regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 38 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 39 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 40 UK market estimates and forecasts, 2018 - 2030
  • Fig. 41 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 42 France market estimates and forecasts, 2018 - 2030
  • Fig. 43 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 45 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 46 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 47 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 48 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 49 China market estimates and forecasts, 2018 - 2030
  • Fig. 50 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 51 India market estimates and forecasts, 2018 - 2030
  • Fig. 52 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 53 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 55 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 56 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 57 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 58 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 60 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 61 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030